SummaryIn this trial, patients will be randomised into one of two arms. In the experimental arm, patients will receive oral olaparib 300mg BD and oral cediranib 20mg OD; in the comparator arm, patients will receive oral olaparib 300mg BD alone. All patients attend hospital for a 2 weekly review for the first 8 weeks, then 4 weekly for year 1 and 8 weekly for year 2 onwards until discontinuation of all trial drugs. Treatment may continue beyond progression until the next line of treatment if the patient is deemed to still be deriving clinical benefit. QOL instruments will be collected at baseline, every clinic visit and continue to be completed after relapse.
This trial is treating patients with ovarian cancer.
Female Reproductive System
Use the hyperlinks, where available to access additional clinical trial information.
University College London Hospitals
International Phase III Randomised Study to Evaluate the Efficacy of Maintenance Therapy With Olaparib and Cediranib or Olaparib Alone in Patients With Relapsed Ovarian Cancer Following a Response to Platinum-based Chemotherapy